| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |